Skip to main content
WEIHAI BAIHE BIOLOGY TECHNOLOGICAL CO., LTD. logo

WEIHAI BAIHE BIOLOGY TECHNOLOGICAL CO., LTD. — Investor Relations & Filings

Ticker · 603102 ISIN · CNE100005RB6 LEI · 655600G6LCXCSY4Q3526 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2026-04-15 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603102

About WEIHAI BAIHE BIOLOGY TECHNOLOGICAL CO., LTD.

http://en.baiheshengwu.com/

Weihai Baihe Biology Technological Co., Ltd. is a contract development and manufacturing organization (CDMO) specializing in the production of dietary supplements and health foods. The company provides comprehensive services including formulation research, product development, and large-scale manufacturing across multiple delivery formats such as softgels, hard capsules, tablets, powders, granules, and oral liquids. Its facilities are equipped with advanced automated production lines and maintain international quality certifications including GMP, ISO, HACCP, and NSF. The company focuses on delivering high-quality nutritional solutions to global markets, utilizing sophisticated extraction and stabilization technologies to ensure ingredient efficacy. Its capabilities extend to private label and OEM/ODM services, supporting diverse requirements for nutritional health and functional food applications.

Recent filings

Filing Released Lang Actions
威海百合生物技术股份有限公司非经营性资金占用及其他关联资金往来情况专项说明
Audit Report / Information Classification · 90% confidence The document is a specialized auditor’s report (“专项说明”) issued by RSM China (an accounting firm) on the non-operating funds occupancy and related-party transactions of Weihai Baihe Biotechnology Co., Ltd. It references the audited 2025 financial statements, includes auditor’s assurance procedures and opinions, and provides detailed schedules. It is not the full annual report nor merely an announcement. It constitutes standalone audit/information related to the company’s applied accounting and internal checks. Therefore it falls under the Audit Report / Information category.
2026-04-15 Chinese
威海百合生物技术股份有限公司董事会对在任独立董事独立性情况评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the current independent directors, referencing regulatory requirements such as the China Securities Regulatory Commission (CSRC) rules and stock exchange business rules. It is a governance-related statement about board members' independence, not a financial report or announcement of voting results. The content fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is short and focused on governance compliance rather than financial data or meeting results.
2026-04-15 Chinese
威海百合生物技术股份有限公司关于更换保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the company's sponsor representative (保荐代表人) for ongoing supervision related to the company's initial public offering (IPO). It details the replacement of one sponsor representative with another and includes a brief resume of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other report types. This fits the category of a regulatory announcement about management or supervisory changes related to the IPO process, which aligns best with Regulatory Filings (RNS) as it does not fit other more specific categories.
2026-04-08 Chinese
威海百合生物技术股份有限公司第五届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement from the board of directors of Weihai Baihe Biotechnology Co., Ltd. It details the resolutions passed at the first meeting of the fifth board of directors, including the election and appointment of the chairman, committee members, general manager, deputy general managers, board secretary, and financial director. The document includes voting results and brief biographies of the appointed individuals. There is no financial data, earnings information, or report publication mentioned. The content focuses exclusively on changes and appointments in the company's board and senior management. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3764 characters, which is consistent with a detailed announcement rather than a brief notice or report publication announcement.
2026-02-27 Chinese
北京市君泽君律师事务所关于威海百合生物技术股份有限公司2026年第一次临时股东会的法律意见
Regulatory Filings Classification · 82% confidence The document is a formal legal opinion letter issued by a law firm regarding the procedural legality and voting results of an extraordinary shareholders’ meeting. It is not a financial report, earnings release, proxy statement, or management presentation. It is a compliance/legal document rather than direct regulatory filings of financial data or announcement of a report publication. Since it functions as a legal compliance submission attached to the shareholders’ meeting materials, it best fits the fallback category of “Regulatory Filings” (RNS).
2026-02-27 Chinese
威海百合生物技术股份有限公司2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2026 first extraordinary shareholders meeting of Weihai Baihe Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including board elections and amendments to company rules, and legal witness statements. The content focuses on the voting results and decisions made at the shareholders meeting rather than the meeting materials or presentations. The document length is about 2710 characters, which is relatively short but contains substantive voting results and resolutions. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. It is not a report publication announcement or a proxy solicitation, but the actual voting results announcement. Therefore, the correct classification is DVA with high confidence.
2026-02-27 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.